CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMADIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY

This article has no abstract
Epistemonikos ID: 924fdfb8d3f9989020094a958e3ea72c74732502
First added on: Feb 16, 2025